Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Huaren Pharma Acquires Hongta Innovation Investment for $550 Million

publication date: Jun 9, 2015
Huaren Pharmaceutical, an IV drugmaker based in Qingdao, Shandong Province, will pay $550 million to acquire an investment company, Hongta Innovation Investment. Hongta holds a 9.2% stake in Huaren, which was worth about $75 million at the time the deal was struck. The investment company's others assets were not disclosed. Huaren will pay for the transaction with $81 million of cash and the remainder in Huraen stock. More details....

Stock Symbol: (SHZ: 300110)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China